PO Box 9530
- Curriculum Vitae
- Download CV
Associate Director for Translational Research
- West Virginia University WVU Cancer Institute
- WVU Cancer Institute Administration
Prof., Benedum Fellow and Douglas Glover Endowed Chair Dept. of Basic Pharmaceutical Sciences
- West Virginia University School of Pharmacy
- Pharmaceutical Sciences
Top 10 papers:
Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Mohammad AS, Griffith JI, Adkins CE, Shah N, Sechrest E, Dolan EL, Terrell-Hall TB, Hendriks BS, Lee H, Lockman PR.
Pharm Res. 2018 Jan 9;35(2):31. doi: 10.1007/s11095-017-2278-0.
Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors.
Mittapalli RK, Adkins CE, Bohn KA, Mohammad AS, Lockman JA, Lockman PR.
Cancer Res. 2017 Jan 15;77(2):238-246. doi: 10.1158/0008-5472.CAN-16-1711. Epub 2016 Nov 4.
Permeability across a novel microfluidic blood-tumor barrier model.
Terrell-Hall TB, Ammer AG, Griffith JI, Lockman PR.
Fluids Barriers CNS. 2017 Jan 23;14(1):3. doi: 10.1186/s12987-017-0050-9.
Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer.
Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JIG, Lockman PR.
Oncotarget. 2017 Jul 26;8(48):83734-83744. doi: 10.18632/oncotarget.19634. eCollection 2017 Oct 13.
Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E, Palmieri D, Liewehr DJ, Steinberg SM, Kloc W, Izycka-Swieszewska E, Duchnowska R, Nayyar N, Brastianos PK, Steeg PS, Gril B.
Clin Cancer Res. 2016 Nov 1;22(21):5287-5299. Epub 2016 May 31.
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall T, Mohan NK, Eldon MA, Hoch U, Lockman PR.
BMC Cancer. 2015 Oct 13;15:685. doi: 10.1186/s12885-015-1672-4.
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD.
Neuro Oncol. 2015 Feb;17(2):289-95. doi: 10.1093/neuonc/nou141. Epub 2014 Jul 11. Erratum in: Neuro Oncol. 2015 Oct;17(10):1423.
Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model.
Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, Qhattal HS, Geldenhuys WJ, Palmieri D, Steeg PS, Smith QR, Lockman PR.
Mol Cancer Ther. 2013 Nov;12(11):2389-99. doi: 10.1158/1535-7163.MCT-13-0132. Epub 2013 Sep 3.
P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model.
Adkins CE, Mittapalli RK, Manda VK, Nounou MI, Mohammad AS, Terrell TB, Bohn KA, Yasemin C, Grothe TR, Lockman JA, Lockman PR.
Front Pharmacol. 2013 Nov 4;4:136. doi: 10.3389/fphar.2013.00136. eCollection 2013.
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR.
Clin Cancer Res. 2010 Dec 1;16(23):5664-78. doi: 10.1158/1078-0432.CCR-10-1564. Epub 2010 Sep 9.
Recent Scientific Awards
TTUHSC President’s Young Investigator Research Award (2009)
TTUHSC School of Pharmacy, Distinguished Alumni Award; Excellence in Research (2010)
Invited Talk; Gordon Research Conference: Barriers of the CNS (2010): Drug delivery to metastatic brain tumors. Colby-Sawyer College, New Hampshire.
Invited Talk; Does Chemotherapy Reach Effective Concentrations for the Treatment of Brain Metastases of Breast Cancer? Medical Rounds – London Health Sciences Center. Invited Seminar and Discussion. London Ontario, Canada
Invited Talk; Breast Cancer Center of Excellence, Invited Panelist and speaker National Breast Cancer Coalition Fund, Annual Advocacy Training Conference, Washington DC.(2009)
Invited Talk; Challenges and Opportunities to Deliver Drugs in Brain Metastases of Breast Cancer, Invited Seminar, MD Anderson Houston TX (2009)
Invited Talk; Workshop on Drug Delivery in Parkinson’s Disease; Circumventing the Blood-brain barrier (2008):Michael J. Fox Foundation and the Kinetics foundation. San Francisco, CA.
Recent Educational Awards
American Association of Colleges of Pharmacy; Innovations in Teaching Award (2007)
Texas Higher Education Coordinating Board Star Award Finalist (2009)
TTUHSC President’s Excellence in Teaching Award (2008)
P3 Teacher of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007, 2008)
P3 Teaching Team of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007)
P1 Teaching Team of the Year; Texas Tech University HSC, SOP (2004)
Teaching: Clinical Toxicology, Anatomy and Pharmacology
About Paul Lockman
Dr. Lockman earned his B.S. in Nursing from West Texas A&M University, after which he practiced in intensive care, clinical toxicology and emergency medicine, then went on to earn his Ph.D. (Pharmaceutical Sciences) at Texas Tech University Health Sciences Center. Dr. Lockman was an Associate Professor and Associate Dean for Outcomes Assessment and Accreditation at Texas Tech University before transitioning to West Virginia University. Currently, Dr. Lockman is the Douglas Glover Endowed Chair of Basic Pharmaceutical Sciences at West Virginia University School of Pharmacy. He also serves as the Associate Director for Translational Research at the Mary Babb Randolph Cancer Center. Dr. Lockman’s primary research focus is on understanding why chemotherapy has limited distribution, and ultimately fails in brain metastases of breast cancer.
Grants and Research
Chemotherapy distribution into brain tumors and metastases
Nanoparticle drug delivery to brain
Effects of nicotine and or smoking on drug distribution
Recent and Current Funding
biOasis; Drug Company Contract “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer; Survival Project”
National Cancer Institute, National Institutes of Health, Bethesda, MD. 1R01CA166067-01A1 “Prevention and Treatment of Brain Micro-metastases of Breast Cancer”
NEKTAR Therapeutics; Drug company contract “Pharmacokinetics and efficacy of NEKTAR-102 in brain metastases of breast cancer”
biOasis; drug company contract “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer”
Department of Defense, Breast Cancer Research Program. #BC096887. Cationic Chemotherapeutics to Penetrate Both the Blood-Brain Barrier and Brain Metastasis of Breast Cancer Cells via the Choline Transporter.
Department of Defense, Breast Cancer Research Program. # BC050006. Blood-Tumor Barrier Characterization and Nanoparticle Drug Delivery in Brain Metastasis of Breast Cancer.
Microtransponder; Medical Device Grant “Feasibility of microstimulation for targeted BBB disruption.”
Minority Health Research and Education Grant program. State of Texas Board of Higher Education; Minority Health Research and Education Grant. Innovations in Competency Education: Strengthening the Pipeline.
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. U19 MH069059-01. Development of Novel Treatments for Nicotine Addiction.”